Novartis AG
COMBINATION OF A BCL-2 INHIBITOR AND A MCL-1 INHIBITOR, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF
Last updated:
Abstract:
A combination comprising a BCL-2 inhibitor and a MCL1 inhibitor, and compositions and uses thereof.
Status:
Application
Type:
Utility
Filling date:
21 Jul 2017
Issue date:
8 Aug 2019